The European healthcare technology and services landscape has entered a structurally distinct phase of maturation, transitioning from the speculative, growth-at-all-costs venture capital paradigms of the post-pandemic era into an era defined by profitable efficiency, clinical validation and platform scale. Following several years of valuation corrections and capital constraints, mergers and acquisitions have become the dominant, necessary exit route for maturing enterprises,